Brokerages expect that Redhill Biopharma Ltd. (NASDAQ:RDHL) will post sales of $1.27 million for the current quarter, according to Zacks. Two analysts have made estimates for Redhill Biopharma’s earnings, with estimates ranging from $900,000.00 to $1.64 million. The business is expected to issue its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Redhill Biopharma will report full-year sales of $1.27 million for the current year, with estimates ranging from $2.78 million to $4.69 million. For the next financial year, analysts forecast that the business will post sales of $47.25 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last released its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by $0.02. The company had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.

Several equities analysts recently weighed in on RDHL shares. Roth Capital set a $26.00 target price on Redhill Biopharma and gave the company a “buy” rating in a research report on Thursday, May 4th. HC Wainwright set a $33.00 target price on Redhill Biopharma and gave the company a “buy” rating in a research report on Thursday, May 4th. Zacks Investment Research upgraded Redhill Biopharma from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research report on Tuesday, July 4th. Finally, FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a research report on Friday, June 16th.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/05/1-27-million-in-sales-expected-for-redhill-biopharma-ltd-nasdaqrdhl-this-quarter.html.

A number of institutional investors have recently added to or reduced their stakes in RDHL. Renaissance Technologies LLC increased its position in Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares during the period. Jane Street Group LLC bought a new position in Redhill Biopharma during the first quarter valued at $276,000. Family Management Corp bought a new position in Redhill Biopharma during the first quarter valued at $163,000. Bank of New York Mellon Corp bought a new position in Redhill Biopharma during the first quarter valued at $101,000. Finally, Penserra Capital Management LLC increased its position in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 7,647 shares during the period. Institutional investors own 12.31% of the company’s stock.

Shares of Redhill Biopharma (NASDAQ:RDHL) opened at 9.03 on Friday. The company’s market capitalization is $154.98 million. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $16.54. The company’s 50 day moving average price is $9.06 and its 200-day moving average price is $9.64.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.